SCA
AEGR

SAC Capital Advisors’s Aegerion Pharmaceuticals AEGR Stock Holding History

SAC Capital Advisors’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-30,700
Closed -$1.95M – 2056
2013
Q2 		$1.95M Buy
+30,700
New +$1.63M 0.01% 760

Other funds holding AEGR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

SAC Capital Advisors's AEGR Position: Q3 2013 in Review

SAC Capital Advisors sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2013, closing a stake of 30,700 shares — an estimated $1.95M sold.

SAC Capital Advisors first reported a position in AEGR in Q2 2013 and held it in 1 quarter. The position peaked at $1.95M in Q2 2013. 154 funds tracked by Wall St. Rank hold AEGR as of Q3 2013.

  • SAC Capital Advisors reported no remaining Aegerion Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • SAC Capital Advisors sold 30,700 Aegerion Pharmaceuticals shares in Q3 2013, an estimated $1.95M.
  • SAC Capital Advisors first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • SAC Capital Advisors's Aegerion Pharmaceuticals position peaked at $1.95M in Q2 2013.
  • 154 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2013.

Based on SAC Capital Advisors's 13F filing for Q3 2013, filed 14 Nov 2013.